Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vaxart Reports Topline Results from Phase 2 Trial of Teslexivir™ for the Treatment of Condyloma
Safety and tolerability profile comparable to placebo Primary efficacy endpoint not achieved - Positive trend in two important subgroups SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 4, 2018-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are
View HTML
Toggle Summary Vaxart to Present at the Jefferies 2018 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 1, 2018-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Wouter Latour , M.D., president and chief executive
View HTML
Toggle Summary Vaxart to Present at ASM Microbe 2018
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 31, 2018-- Vaxart, Inc. (NASDAQ:VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo , Ph.D., lead scientist of Vaxart , will
View HTML
Toggle Summary Vaxart Announces First Quarter 2018 Financial Results and Corporate Update
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 15, 2018-- Vaxart, Inc. (Nasdaq:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the first quarter ended March 31,
View HTML
Toggle Summary Vaxart Appoints Dr. David Taylor as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 1, 2018-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of David Taylor , M.D., as Chief Medical Officer. Dr.
View HTML
Toggle Summary Vaxart Announces $5 Million Inavir® Revenue Milestone
2017 Net Sales of Inavir ® in Japan Exceeded ¥20 Billion, Triggering USD $5 Million Milestone Payment SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 20, 2018-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than
View HTML
Toggle Summary Vaxart Appoints Brant Biehn as Senior Vice President, Commercial Operations
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 19, 2018-- Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of Brant Biehn as Senior Vice President,
View HTML
Toggle Summary Vaxart to Present at Two Upcoming Medical Meetings
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 16, 2018-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that new preclinical data on its intranasal Chikungunya
View HTML
Toggle Summary Vaxart Announces Oral Presentation of Clinical Data from Oral Influenza Vaccine Program at the World Vaccine Congress
SOUTH SAN FRANCISCO, Calif., April 2, 2018 — Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that the complete clinical dataset from the Phase 2 Challenge Study of its H1
View HTML
Toggle Summary Vaxart to Present at the 17th Annual Needham Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that Wouter Latour , M.D., president and chief executive officer of Vaxart , will
View HTML
Toggle Summary Vaxart Expands Intellectual Property Portfolio With U.S. Patent Allowance
Issued Claims Cover High Yield Production Process of Phase 2 Antiviral SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Vaxart, Inc. (NASDAQ: VXRT) a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that the
View HTML
Toggle Summary Vaxart to Present Clinical Data From Oral Norovirus Vaccine Program at International Congress on Infectious Diseases
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it will present clinical data from two Phase 1 studies of its
View HTML
Toggle Summary Vaxart, Inc. Closes Merger with Aviragen Therapeutics, Inc.
Vaxart, Inc. Closes Merger with Aviragen Therapeutics, Inc. Combined Company Renamed Vaxart, Inc. and Will Begin Trading Under New Symbol NASDAQ: VXRT SOUTH SAN FRANCISCO, CA and ATLANTA, Feb. 13, 2018 — Vaxart, Inc. (NASDAQ: VXRT) today announced the completion of its merger with Aviragen
View HTML
Toggle Summary Aviragen Adjourns Special Meeting of Stockholders to Allow Stockholders to Consider Improved Merger Deal Terms
CAS Group Supports Improved Deal Company Currently has Sufficient Votes to Approve Merger ATLANTA , Feb. 09, 2018 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced that the reconvened Special Meeting of Stockholders has been further adjourned to 10:00 AM, EST on February
View HTML
Toggle Summary Vaxart Provides Merger Update View HTML

Log In

Create an account